

AbCellera to develop therapeutics to combat Diabetic Retinopathy blindness

10 May 2021 | News

Three-target, multi-year collaboration includes the development of bispecific antibodies to treat sight-threatening complication of type 1 and 2 diabetes



AbCellera and Angios GmbH announced a multi-year, multi-target collaboration to facilitate the discovery of monoclonal and bispecific antibodies for vascular diseases of the eye. AbCellera will use its full-stack, AI-powered antibody discovery platform to generate panels of antibodies for up to three Angios-selected targets to address diabetic retinopathy.

“Through this collaboration, Angios can focus on advancing their unique scientific insights for treating blindness in diabetes, rather than on establishing and scaling internal antibody discovery capabilities,” said Carl Hansen, Ph.D., CEO and President of AbCellera. “We are excited to work closely with Angios to start their programs without delay, including identifying bispecific antibodies against diabetic retinopathy and moving them forward at maximum speed.”

Under the terms of the agreement, Angios will have the rights to develop and commercialize therapeutic products resulting from the collaboration. AbCellera will receive equity and research fees and is eligible for milestone payments and royalties based on the development and commercialization of antibodies generated by AbCellera under this collaboration.